NYSE:VNRX VolitionRx (VNRX) Stock Price, News & Analysis $0.52 -0.05 (-9.03%) Closing price 04:00 PM EasternExtended Trading$0.52 0.00 (-0.12%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock About VolitionRx Stock (NYSE:VNRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get VolitionRx alerts:Sign Up Key Stats Today's Range$0.51▼$0.5950-Day Range$0.51▼$0.6452-Week Range$0.43▼$1.02Volume243,187 shsAverage Volume177,079 shsMarket Capitalization$48.06 millionP/E RatioN/ADividend YieldN/APrice Target$3.75Consensus RatingModerate Buy Company OverviewVolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.Read More… Remove Ads VolitionRx Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScoreVNRX MarketRank™: VolitionRx scored higher than 40% of companies evaluated by MarketBeat, and ranked 718th out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingVolitionRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageVolitionRx has only been the subject of 1 research reports in the past 90 days.Read more about VolitionRx's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of VolitionRx is -1.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of VolitionRx is -1.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for VNRX. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVolitionRx does not currently pay a dividend.Dividend GrowthVolitionRx does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for VNRX. News and Social Media2.6 / 5News Sentiment0.67 News SentimentVolitionRx has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for VolitionRx this week, compared to 1 article on an average week.MarketBeat Follows2 people have added VolitionRx to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, VolitionRx insiders have bought more of their company's stock than they have sold. Specifically, they have bought $100,000.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders12.80% of the stock of VolitionRx is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 8.09% of the stock of VolitionRx is held by institutions.Read more about VolitionRx's insider trading history. Receive VNRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VolitionRx and its competitors with MarketBeat's FREE daily newsletter. Email Address VNRX Stock News HeadlinesInsider Buying: VolitionRx Limited (NYSE:VNRX) CEO Acquires 181,818 Shares of StockMarch 28, 2025 | insidertrades.comVolitionRx outlines 2025 licensing goals and targets cash neutrality with strategic expansionsApril 1 at 2:10 AM | msn.comPartner with Elon Musk on Project Colossus… Before May 1stEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you… To partner with Elon on what he believes will be the biggest AI project of the century… Starting with as little as $500.April 1, 2025 | Brownstone Research (Ad)VolitionRx Limited (VNRX) Q4 2024 Earnings Call TranscriptApril 1 at 1:03 AM | seekingalpha.comVolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business UpdateMarch 31 at 4:05 PM | prnewswire.com3VNRX : A Look Ahead: VolitionRX's Earnings ForecastMarch 28, 2025 | benzinga.comVolition Announces Two Poster Presentations at ESMO's European Lung Cancer Congress 2025March 28, 2025 | prnewswire.comVolition to Host Virtual Investor Event on Nu.Q® Cancer, "A Look to the Future of Cancer Diagnostics", on April 9, 2025March 27, 2025 | prnewswire.comSee More Headlines VNRX Stock Analysis - Frequently Asked Questions How have VNRX shares performed this year? VolitionRx's stock was trading at $0.60 at the beginning of the year. Since then, VNRX shares have decreased by 13.6% and is now trading at $0.5186. View the best growth stocks for 2025 here. How were VolitionRx's earnings last quarter? VolitionRx Limited (NYSE:VNRX) announced its quarterly earnings results on Monday, March, 25th. The company reported ($0.11) EPS for the quarter. The business earned $0.24 million during the quarter, compared to the consensus estimate of $0.50 million. How do I buy shares of VolitionRx? Shares of VNRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of VolitionRx own? Based on aggregate information from My MarketBeat watchlists, some other companies that VolitionRx investors own include BlackRock Innovation and Growth Term Trust (BIGZ), FS KKR Capital (FSK), Guggenheim Strategic Opportunities Fund (GOF), 3M (MMM), OFS Credit (OCCI), XAI Octagon Floating Rate & Alternative Income Trust (XFLT) and Broadcom (AVGO). Company Calendar Last Earnings3/25/2024Today4/01/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Diagnostic substances Sub-IndustryPharmaceutical Products Current SymbolNYSE:VNRX CIK93314 WebN/A Phone646-650-1351Fax65 32 8172 5651Employees80Year FoundedN/APrice Target and Rating Average Stock Price Target$3.75 High Stock Price Target$5.00 Low Stock Price Target$2.50 Potential Upside/Downside+623.1%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,320,000.00 Net Margins-2,321.14% Pretax Margin-2,346.62% Return on EquityN/A Return on Assets-163.39% Debt Debt-to-Equity RatioN/A Current Ratio0.22 Quick Ratio0.22 Sales & Book Value Annual Sales$1.29 million Price / Sales37.37 Cash FlowN/A Price / Cash FlowN/A Book Value($0.11) per share Price / Book-4.71Miscellaneous Outstanding Shares92,665,000Free Float80,804,000Market Cap$48.06 million OptionableOptionable Beta1.09 These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NYSE:VNRX) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | SponsoredBrace Yourself for Jeff Bezos’ “Amazon Helios”Jeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VolitionRx Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share VolitionRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.